All the news Showing 5 of 15 articles from: EASL 2017Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment in cirrhosis New AbbVie hepatitis C combination cures 99% of people with cirrhosis Keith Alcorn / 21 April 2017 A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side-effects, ... Hepatocellular carcinoma (HCC) Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies Liz Highleyman / 21 April 2017 People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher ... Treatment outcomes Curing hepatitis C reduces cardiovascular risk Keith Alcorn / 20 April 2017 Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in Amsterdam shows. Presenting the findings, Patrice ... Access to medicines & diagnostics European HCV treatment access survey shows big variations in eligibility Keith Alcorn / 20 April 2017 England, Malta, Slovakia, Hungary and Croatia have the tightest restrictions on who can receive direct-acting antiviral (DAA) treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland and the Netherlands are the least ... Treatment in cirrhosis Antibiotic prophylaxis reduces the risk of short-term death in people with decompensated cirrhosis Keith Alcorn / 20 April 2017 Long-term prophylaxis with the antibiotic norfloxacin significantly reduced the incidence of deaths in people with decompensated cirrhosis over a six-month follow-up period, a French randomised trial reported today at the International Liver Congress ... ← Prev12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive